Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Accounts Payables (2017 - 2025)

Denali Therapeutics (DNLI) has disclosed Accounts Payables for 9 consecutive years, with $6.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables fell 29.7% to $6.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $6.7 million, a 29.7% decrease, with the full-year FY2024 number at $11.1 million, up 17.44% from a year prior.
  • Accounts Payables was $6.7 million for Q3 2025 at Denali Therapeutics, down from $10.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $13.9 million in Q2 2024 to a low of $1.6 million in Q1 2021.
  • A 5-year average of $7.7 million and a median of $8.5 million in 2025 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 346.22% in 2021, then plummeted 41.62% in 2022.
  • Denali Therapeutics' Accounts Payables stood at $4.8 million in 2021, then tumbled by 41.62% to $2.8 million in 2022, then surged by 239.89% to $9.5 million in 2023, then increased by 17.44% to $11.1 million in 2024, then tumbled by 39.44% to $6.7 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Accounts Payables are $6.7 million (Q3 2025), $10.8 million (Q2 2025), and $8.5 million (Q1 2025).